U.S. Markets open in 5 hrs 29 mins

Cocrystal Pharma, Inc. (COCP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4700-0.6700 (-31.31%)
At close: 4:00PM EDT

Cocrystal Pharma, Inc.

19805 North Creek Parkway
Bothell, WA 98011
United States
786 459 1831
http://www.cocrystalpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Gary L. WilcoxCo-Founder, Chairman & CEO201kN/A1947
Dr. Sam LeeCo-Founder & Pres241kN/A1960
Mr. James J. Martin CPA, M.B.A., CPA, MBACFO & Corp. Sec.231kN/A1967
Dr. Roger D. KornbergCo-Founder, Chairman of Scientific Advisory Board, Chief Scientist & DirectorN/AN/A1947
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Corporate Governance

Cocrystal Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.